Revlimid (Lenalidomide)
lenalidomide — immunomodulatory imide drug (IMiD)
Indications for Lenalidomide
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Multiple myeloma (MM) — all lines | Adults | Combination with dexamethasone | FDA Approved |
| MM — maintenance following auto-HSCT | Adults | Monotherapy maintenance | FDA Approved |
| Myelodysplastic syndromes (MDS) — del(5q) | Adults; transfusion-dependent anaemia; low/int-1 risk | Monotherapy | FDA Approved |
| Mantle cell lymphoma (MCL) — relapsed/refractory | Adults; after ≥2 prior therapies (one including bortezomib) | Monotherapy | FDA Approved |
| Follicular lymphoma (FL) — previously treated | Adults | Combination with rituximab product | FDA Approved |
| Marginal zone lymphoma (MZL) — previously treated | Adults | Combination with rituximab product | FDA Approved |
Lenalidomide is a cornerstone immunomodulatory agent in haematological oncology. First approved in 2005 for MDS, it received its broadest indication in 2015 when the FDA approved lenalidomide with dexamethasone for all lines of multiple myeloma therapy. It is a structural analogue of thalidomide with enhanced immunomodulatory, anti-angiogenic, and direct antineoplastic activity. Because of its teratogenic potential, lenalidomide is available only through the mandatory Lenalidomide REMS program, requiring prescriber certification, patient enrolment, and pharmacy certification.
Myelofibrosis — used as second-line therapy, particularly in patients with del(5q). Evidence quality: Moderate.
Systemic AL amyloidosis — in combination with dexamethasone for relapsed/refractory disease. Evidence quality: Moderate.
Diffuse large B-cell lymphoma (DLBCL) — R² regimen (lenalidomide + rituximab) in non-GCB subtype. Evidence quality: Moderate (RE-MIND trial).
Lenalidomide is not indicated and not recommended for the treatment of chronic lymphocytic leukaemia (CLL) outside of controlled clinical trials. A randomised trial showed increased mortality (HR 1.92) with lenalidomide versus chlorambucil in first-line CLL (FDA PI Section 5.5).
Dosing for Lenalidomide
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Multiple myeloma — combination therapy (all lines) | 25 mg PO daily, Days 1–21 of 28-day cycles | 25 mg PO daily, Days 1–21 | 25 mg/day | With dexamethasone (see PI Section 14.1 for specific dex dosing by study); preferred low-dose schedule: 40 mg on Days 1, 8, 15, 22 (FIRST trial); reduce dex for age >75; continue until progression Plan stem cell mobilisation within 4 cycles if HSCT-eligible |
| MM — maintenance post-auto-HSCT | 10 mg PO daily, Days 1–28 continuously | Increase to 15 mg daily after 3 cycles if tolerated | 15 mg/day | Initiate after haematologic recovery (ANC ≥1000, platelets ≥75,000); continue until progression Continuous dosing (no 7-day rest period) |
| MDS with del(5q) — transfusion-dependent anaemia | 10 mg PO daily continuously | 10 mg PO daily (dose-reduce per haem tox tables) | 10 mg/day | Continue until progression; 80% of patients require dose delay/reduction; 34% need a second reduction Detailed dose reduction tables in PI for thrombocytopenia and neutropenia based on baseline counts and timing |
| Mantle cell lymphoma — relapsed/refractory | 25 mg PO daily, Days 1–21 of 28-day cycles | 25 mg PO daily, Days 1–21 | 25 mg/day | Monotherapy; continue until progression; reduce by 5 mg per step for haem toxicity (minimum 5 mg daily) |
| Follicular lymphoma or marginal zone lymphoma — previously treated | 20 mg PO daily, Days 1–21 of 28-day cycles | 20 mg PO daily, Days 1–21 | Up to 12 cycles | In combination with rituximab; treatment capped at 12 cycles Reduce by 5 mg per step for haem toxicity (minimum 5 mg daily) |
Renal Dose Adjustments
| Renal Function (CrCl) | MM Combination / MCL | FL / MZL | MM Maintenance / MDS | Notes |
|---|---|---|---|---|
| CrCl 30–60 mL/min | 10 mg once daily | 10 mg once daily | 5 mg once daily | May escalate to 15 mg after 2 cycles if tolerated (MM/FL/MZL) |
| CrCl <30 mL/min (no dialysis) | 15 mg every other day | 5 mg once daily | 2.5 mg once daily | Close monitoring for haematologic toxicity |
| CrCl <30 mL/min (on dialysis) | 5 mg once daily | 5 mg once daily | 2.5 mg once daily | Administer dose after dialysis on dialysis days 4-h haemodialysis removes ~31% of lenalidomide |
Lenalidomide impairs stem cell mobilisation. In HSCT-eligible patients, plan collection within the first 4 cycles of lenalidomide-containing therapy. Delayed mobilisation after prolonged lenalidomide exposure may result in inadequate CD34+ cell yields and compromise transplant feasibility (FDA PI Section 5.12).
Pharmacology of Lenalidomide
Mechanism of Action
Lenalidomide exerts its therapeutic effects through binding to cereblon (CRBN), a substrate receptor of the CRL4CRBN E3 ubiquitin ligase complex. This binding redirects the ubiquitin ligase to degrade specific transcription factors, most notably the lymphoid transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), leading to direct cytotoxicity in myeloma cells and enhanced T-cell and NK-cell activation. In del(5q) MDS, lenalidomide selectively targets casein kinase 1α (CK1α), a haploinsufficient gene product in del(5q) cells, for ubiquitin-dependent degradation, providing the molecular basis for the exquisite sensitivity of del(5q) MDS to lenalidomide. Additionally, lenalidomide possesses anti-angiogenic properties through inhibition of VEGF and bFGF, modulates cytokine production (increasing IL-2 and IFN-γ, decreasing TNF-α and IL-6), and enhances antibody-dependent cellular cytotoxicity (ADCC).
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Rapidly absorbed; Tmax 0.5–6 h (median ~1 h); oral bioavailability ≥82%; linear, dose-proportional PK; food reduces Cmax by ~50% and AUC by ~20% | May be taken with or without food (food effect deemed clinically insignificant by FDA); swallow capsules whole, do not open or crush |
| Distribution | Vd 75–125 L (apparent); protein binding ~30%; distributes into semen (undetectable 3 days after stopping) | Low protein binding means dialysis can remove the drug (~31% per 4-h session); semen distribution necessitates male contraception requirements |
| Metabolism | Minimal hepatic metabolism; not a CYP450 substrate, inhibitor, or inducer; two minor metabolites (5-hydroxy-lenalidomide, N-acetyl-lenalidomide, each <5% of dose) | No dose adjustment needed for mild hepatic impairment; no CYP450-based drug interactions expected; safe for polypharmacy from a PK interaction standpoint |
| Elimination | t½ 3–4 h (normal renal function); 9–10 h (moderate/severe RI); ~16 h (ESRD); ~82% excreted unchanged in urine within 24 h; 90% of radioactive dose recovered in urine | Renal function is the primary determinant of exposure; dose reduction required for CrCl <60 mL/min; short half-life means no accumulation with daily dosing |
Side Effects of Lenalidomide
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Diarrhoea | ≥20% | Among the most frequent GI effects; manage with loperamide |
| Fatigue / asthenia | ≥20% | Common across all indications; dose-related |
| Constipation | ≥20% | May reflect concurrent dexamethasone or opioid use |
| Neutropenia | ≥20% (Grade 3/4: up to 59% maintenance) | Dose-limiting toxicity; requires CBC monitoring per indication-specific schedules |
| Thrombocytopenia | ≥20% (Grade 3/4: up to 38% maintenance) | Monitor for bleeding; dose interruption/reduction per protocol |
| Anaemia | ≥20% | May require transfusion support or ESA use (note: ESA increases VTE risk) |
| Muscle cramps / spasms | ≥20% | Often nocturnal; magnesium supplementation may help |
| Peripheral oedema | ≥20% | Differentiate from cardiac or renal causes |
| Upper respiratory infection / nasopharyngitis | ≥20% | Reflects immunomodulatory effect; assess for serious infection |
| Rash | ≥15–20% | Usually mild; discontinue for SJS/TEN or Grade 4 rash |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Deep vein thrombosis | 7.4% (relapsed MM with Rd vs 3.1% placebo) | Part of the class-wide thrombotic risk; thromboprophylaxis required (see Serious tier for full VTE details) |
| Pulmonary embolism | 3.7% (relapsed MM with Rd vs 0.9% placebo) | Can be fatal; advise patients to report sudden dyspnoea or chest pain immediately |
| Hypothyroidism | Reported | Thyroid disorders observed; monitor TSH if symptoms develop (PI Section 5.13) |
| Elevated liver enzymes | 2% serious (MM) | Part of hepatotoxicity spectrum; stop lenalidomide for significant LFT elevation |
| Tremor | ≥5% (MM) | Listed among common MM adverse reactions; usually mild |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Venous thromboembolism (DVT, PE) | DVT 7.4% vs 3.1%; PE 3.7% vs 0.9% (relapsed MM) | Median 2.8 months to first event | Thromboprophylaxis recommended for all patients; based on individual risk assessment (aspirin, LMWH, or warfarin) |
| Arterial thromboembolism (MI, stroke) | MI 1.7% vs 0.6%; stroke 2.3% vs 0.9% | Variable | Modify risk factors; immediate cardiology/neurology referral |
| Severe neutropenia (Grade 3/4) | 48% (MDS); 43% (MCL); up to 59% (MM maintenance) | MDS: median 42 days (range 14–411) | Dose interruption per protocol; G-CSF support if needed; MDS recovery median 17 days |
| Severe thrombocytopenia (Grade 3/4) | 28–54% (indication-dependent) | MDS: median 28 days (range 8–290) | Dose interruption per protocol; platelet transfusion if needed; MDS recovery median 22 days |
| Second primary malignancies (SPM) | AML/MDS: 0.4% (Rd); 5.3% (with melphalan); 7.5% (post-HSCT maintenance) | Variable; requires long-term surveillance | Monitor for development of SPM; weigh benefit vs. risk; risk highest with alkylating agent combinations |
| Embryo-fetal toxicity | Teratogenic in primates at all doses tested | Any exposure during pregnancy | Absolute contraindication in pregnancy; REMS program mandatory; 2 forms of contraception; 2 negative pregnancy tests before starting |
| Hepatotoxicity (including fatal hepatic failure) | 15% any hepatotoxicity; 2% serious (MM) | Variable | Monitor liver enzymes periodically; stop lenalidomide for elevated LFTs; may restart at lower dose after normalisation |
| Severe cutaneous reactions (SJS, TEN) | Rare; can be fatal | Variable | Permanently discontinue; do not rechallenge; dermatology referral |
| Tumour lysis syndrome | Rare; fatal cases reported | Early cycles; high tumour burden | Monitor electrolytes, uric acid, renal function in high-risk patients; prophylactic hydration and allopurinol |
| Tumour flare reaction | Reported in CLL and lymphoma (including fatal) | Early treatment cycles | Monitor in MCL; characterised by tender lymphadenopathy, fever, rash; not an indication for CLL use |
All patients receiving lenalidomide with dexamethasone should receive thromboprophylaxis. The choice of agent (aspirin, LMWH, or warfarin) should be based on individual patient risk assessment. Without prophylaxis, thrombotic events occurred in 21.5% of patients. With prophylaxis in the NDMM FIRST study, the overall thrombotic event rate was reduced to 17.4% (FDA PI Section 5.4). ESA and oestrogen-containing therapies further increase thrombosis risk and should be used with caution.
Drug Interactions with Lenalidomide
Lenalidomide has a favourable drug interaction profile because it is not metabolised by CYP450 enzymes, is not a P-glycoprotein substrate of clinical significance, and is primarily renally eliminated. The main interaction concerns are pharmacodynamic, centred on additive thrombotic risk and monitoring of co-administered drugs whose levels may change.
Monitoring for Lenalidomide
- CBC with DifferentialMM: weekly ×2 cycles, Days 1+15 Cycle 3, then q4wk; MDS: weekly ×8 wk, then ≥monthly; MCL: weekly Cycle 1, q2wk Cycles 2–4, then monthly; FL/MZL: weekly ×3 wk Cycle 1, q2wk Cycles 2–4, then monthly
RoutineHaematologic toxicity is dose-limiting. Follow indication-specific CBC schedules exactly. Dose interrupt/reduce per protocol for Grade 3/4 neutropenia or thrombocytopenia. - Pregnancy Testing2 negative tests before starting (10–14 days apart, second within 24 h of first dose); weekly ×4 wk, then q4wk (regular cycles) or q2wk (irregular)
RoutineMandatory REMS requirement for all females of reproductive potential. Must be documented before each prescription. - Renal FunctionBaseline and periodically
RoutinePrimary route of elimination is renal; dose adjustment required for CrCl <60 mL/min. Renal impairment common in MM (~50% of patients). - Liver Function TestsPeriodically
RoutineHepatotoxicity reported in 15% (any grade); serious in 2%. Stop lenalidomide for elevated LFTs; may restart at lower dose after normalisation. - Signs of VTE / ATEEach cycle
Trigger-basedAdvise patients to report leg swelling, chest pain, shortness of breath, arm weakness, or sudden severe headache immediately. Ensure thromboprophylaxis is prescribed. - Second Primary MalignanciesLong-term surveillance
Trigger-basedAML/MDS risk increased, especially with alkylating agents. Age-appropriate cancer screening; haematology review for unexplained cytopenias. - Thyroid FunctionPeriodically
Trigger-basedThyroid disorders (hypothyroidism and hyperthyroidism) reported; monitor TSH if symptoms develop.
Contraindications & Cautions for Lenalidomide
Absolute Contraindications
- Pregnancy — Lenalidomide is a thalidomide analogue; teratogenic in primates at all doses. Limb abnormalities observed. Contraindicated in females who are pregnant (Boxed Warning, PI Section 4.1).
- Severe hypersensitivity to lenalidomide — Including angioedema, SJS, or TEN. Do not rechallenge (PI Section 4.2).
Relative Contraindications (Specialist Input Recommended)
- Chronic lymphocytic leukaemia (CLL) — Increased mortality observed in a randomised trial (HR 1.92); not recommended outside controlled clinical trials.
- Severe renal impairment without appropriate dose adjustment — AUC increases 200–400% in moderate-to-severe RI; dose reduction mandatory.
- High thrombotic risk without feasible anticoagulation — Consider whether the benefit of lenalidomide outweighs the VTE/ATE risk if thromboprophylaxis cannot be administered.
Use with Caution
- High tumour burden — Risk of tumour lysis syndrome (fatal cases reported); monitor electrolytes, hydrate, and consider allopurinol prophylaxis.
- MCL patients — Higher early mortality rate observed; careful patient selection required.
- Lactose intolerance — Capsules contain lactose; evaluate risk-benefit.
- HSCT-eligible patients on prolonged treatment — Impaired stem cell mobilisation after >4 cycles; early transplant centre referral recommended.
Lenalidomide is a thalidomide analogue. Thalidomide causes severe, life-threatening birth defects. Lenalidomide caused limb abnormalities in monkey offspring at all doses tested. Pregnancy must be excluded before starting treatment, and two forms of contraception are required. Available only through the Lenalidomide REMS program.
Significant neutropenia and thrombocytopenia occur across all indications. In del(5q) MDS, 80% of patients experienced Grade 3/4 haematologic toxicity, and 80% required dose delays or reductions. CBC monitoring on indication-specific schedules is mandatory.
Significantly increased risk of DVT, PE, MI, and stroke in patients receiving lenalidomide with dexamethasone. Thromboprophylaxis is recommended for all patients. Without prophylaxis, 21.5% of relapsed MM patients experienced thrombotic events versus 8.3% with placebo. Advise patients to seek immediate medical care for symptoms of thrombosis.
Patient Counselling for Lenalidomide
Purpose of Therapy
Lenalidomide is a capsule taken by mouth that works by modifying the immune system, directly killing cancer cells, and starving tumours of their blood supply. It is used to treat multiple myeloma, certain bone marrow disorders (MDS), and some types of lymphoma. Treatment duration varies by indication but may continue for years in myeloma.
How to Take
Take capsules whole at approximately the same time each day, with or without food. Do not open, break, or chew capsules. Store at room temperature. Do not donate blood during treatment or for 4 weeks after stopping.
Sources
- Revlimid (lenalidomide) capsules. Full Prescribing Information. Bristol-Myers Squibb (Celgene). Revised March 2023. FDA LabelPrimary source for all dosing, boxed warnings, adverse reactions, REMS requirements, and renal dose adjustments in this monograph.
- Lenalidomide REMS Program. Information available at lenalidomiderems.com.Official REMS program website for prescriber certification, patient enrolment, and pharmacy requirements.
- Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma (FIRST/MM-020). N Engl J Med. 2014;371(10):906-917. doi:10.1056/NEJMoa1402551FIRST trial establishing continuous Rd as standard first-line therapy for transplant-ineligible NDMM patients.
- Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357(21):2133-2142. doi:10.1056/NEJMoa070596MM-009 pivotal trial establishing Rd as standard for relapsed MM, demonstrating superior TTP and OS vs dexamethasone alone.
- Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma (MM-010). N Engl J Med. 2007;357(21):2123-2132. doi:10.1056/NEJMoa070594International companion trial to MM-009 confirming efficacy of Rd in relapsed/refractory MM.
- List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456-1465. doi:10.1056/NEJMoa061292Pivotal MDS-003 trial demonstrating 67% transfusion independence rate and 45% cytogenetic response in del(5q) MDS patients.
- McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35(29):3279-3289. doi:10.1200/JCO.2017.72.6679Meta-analysis of 3 RCTs (CALGB 100104, IFM 2005-02, GIMEMA RV-MM-PI-0209) confirming PFS and OS benefit of lenalidomide maintenance post-ASCT.
- Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019;37(14):1188-1199. doi:10.1200/JCO.19.00010AUGMENT trial establishing R² (lenalidomide + rituximab) as standard for relapsed FL and MZL.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 5.2024. NCCNCurrent NCCN guidelines incorporating lenalidomide across all lines of MM therapy and maintenance.
- Krönke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343(6168):301-305. doi:10.1126/science.1244851Landmark mechanistic study identifying cereblon-mediated degradation of Ikaros and Aiolos as the molecular basis for lenalidomide activity in MM.
- Krönke J, Fink EC, Hollenbach PW, et al. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature. 2015;523(7559):183-188. doi:10.1038/nature14610Discovery of CK1α as the del(5q)-specific target of lenalidomide, explaining its selective efficacy in this MDS subtype.
- Chen N, Zhou S, Palmisano M. Clinical pharmacokinetics and pharmacodynamics of lenalidomide. Clin Pharmacokinet. 2017;56(2):139-152. doi:10.1007/s40262-016-0432-1Comprehensive PK review establishing half-life of 3–4 h, renal-dominant elimination, and AUC-matched dose adjustments for renal impairment.
- Hoffmann M, Kasserra C, Reyes J, et al. Absorption, metabolism and excretion of [14C]-lenalidomide following oral administration in healthy male subjects. Cancer Chemother Pharmacol. 2012;69(3):789-797. doi:10.1007/s00280-011-1760-3Mass balance study confirming ≥82% oral bioavailability, 90% urinary recovery, and minimal hepatic metabolism of lenalidomide.